Combination therapy for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced colorectal cancer that cannot be surgically removed.
- You have at least one tumor that can be measured on imaging scans.
- You are physically active and able to care for yourself (ECOG 0-1).
- Your major organs (blood, liver, kidneys, heart) must be working well enough.
- You must not have had certain prior treatments or conditions (e.g., prior irinotecan, dMMR/MSI-H or BRAF V600E mutations, recent blood clots, severe bleeding, or brain metastases).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
This trial tests a new drug combination for colorectal cancer that has not responded to other treatments. It compares the new drug with a standard treatment to see which is more effective.
This trial tests a new drug combination for people with advanced colorectal cancer that cannot be removed by surgery. It aims to see if the treatment can shrink tumors and help patients live longer.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial combines a special type of radiation, immunotherapy, a targeted blood-vessel drug, and a chemotherapy pill for patients whose colorectal cancer has continued to grow after two prior treatments. The hope is that this combination can shrink tumors or slow down the cancer better than current options.
This trial tests a new form of the chemotherapy drug irinotecan (called irinotecan liposome) combined with two other chemo drugs and a targeted therapy (bevacizumab) for people with advanced colorectal cancer that has already been treated with oxaliplatin. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.